Sanofi Acquires Dynavax for $2.2 Billion to Boost Vaccine Portfolio

French drugmaker Sanofi agrees to purchase U.S. vaccines company Dynavax Technologies for $2.2 billion, gaining access to hepatitis B vaccine and experimental shingles shot.